BIONTECH SE SPON. ADRS 1
Commented by Stefan Feulner on September 30th, 2021 | 12:20 CEST
BioNTech, Sativa Wellness Group, Aurora Cannabis - For the good of humanity
One thing has been brought home to humanity since the outbreak of the Corona Pandemic and the rapid development of vaccines - Science and research are essential in identifying health risks and helping people live long and healthy lives. Young companies, in particular, are discovering alternative treatments through their research and using natural products that have centuries of tradition - with great potential.
Read
Commented by Carsten Mainitz on September 28th, 2021 | 11:19 CEST
Cardiol Therapeutics, BioNTech, Valneva - Volatility offers good opportunities!
The share prices of the Corona vaccine manufacturers are not growing sky-high after all. Most recently, developments at France's Valneva caused uncertainty. The French Company wanted to bring a Corona vaccine to market by the end of 2021 and had already received an order from the British government for 100 million units. This contract has now been canceled. Where does the industry go from here?
Read
Commented by Nico Popp on September 27th, 2021 | 10:46 CEST
BioNTech, Meta Materials, Bayer: Rich with innovations
A new car manufacturer or a new networked fitness device can trigger hype on the stock market. But the opportunities are even greater when companies bring genuine innovations to market. These include new active ingredients, pharmacological processes or pioneering achievements by engineers. We present innovators of yesterday, today and tomorrow and shed light on their growth prospects.
Read
Commented by Fabian Lorenz on September 24th, 2021 | 14:10 CEST
BioNTech, Valneva, Defence Therapeutics: New highs for vaccine stocks?
Investors in COVID-19 vaccine manufacturers have had little reason to rejoice in recent weeks. Top dogs Moderna and BioNTech have come back noticeably from their highs. Valneva's stock plummeted on Monday. Only newcomer Defence Therapeutics has held its ground at a high level. But for all of them, the calm could soon be over, and a new high could begin. Because people in other parts of the world are still not vaccinated. In addition, winter is just around the corner in Western countries, which means that Corona rates are rising. In addition, a new study shows the risk of long-COVID - such as memory and concentration deficits - even in children. With this mix, vaccine stocks face an exciting fall.
Read
Commented by Stefan Feulner on September 20th, 2021 | 12:05 CEST
Valneva, Cardiol Therapeutics, BioNTech - Recurring businesses
The vaccination rate is stalling. Around 4 million out of 24 million people over the age of 60 are still unvaccinated. Politicians led by Health Minister Jens Spahn have now launched a vaccination campaign week to get more people immunized against the coronavirus. The proportion of vaccinated people in Germany is still too low to prevent a new Corona wave and a possible resulting overload of the healthcare system. Meanwhile, vaccine producers are already working on the approval of booster shots. Profits should continue to bubble up for a long time.
Read
Commented by Nico Popp on September 14th, 2021 | 13:10 CEST
BioNTech, Defence Therapeutics, Valneva: Here, the overall market (almost) does not matter
Is the crash coming or not? Meanwhile, even Wall Street banks are warning of an imminent crash event. Many commentators are jumping on the bandwagon. The reasons: Delta variation, supply problems and inflation, and an economy that could suffer. But if you compare the crashes of the past years, one thing becomes clear: Only the fewest price setbacks came with notice! We present three stocks that many investors believe can combine growth and security.
Read
Commented by André Will-Laudien on September 10th, 2021 | 12:43 CEST
NanoRepro, XPhyto Therapeutics, BioNTech, Valneva - The next biotech wave is rolling!
So far, vaccine manufacturers can maintain their high valuation because the next wave of new infections is rolling in. In Germany, tests will be subject to fees starting in October, making public life more expensive for those who want to participate. In surveys, most German citizens have expressed support for fee-based testing; probably, the populations here should be separated into "vaccinated" and "unvaccinated" to indicate general opinion accurately. Four interesting values benefit from the current situation.
Read
Commented by Stefan Feulner on September 6th, 2021 | 14:25 CEST
BASF, Desert Gold, Moderna, BioNTech - Keep going, keep going!
The Delta variant is teaching the markets to be afraid. After the economy was humming in the past two quarters, disillusionment is now slowly setting in. The unexpectedly weak labor market data in the US in August demonstrated this. Outside of agriculture, only 235,000 new jobs were created compared with the forecast of 728,000 new jobs. Thus, the market's fear of an end to loose monetary policy and possible interest rate hikes should also be off the table.
Read
Commented by Fabian Lorenz on August 31st, 2021 | 10:37 CEST
Sales explosion? Novavax and Diamcor on the trail of BioNTech
When companies suddenly report strong jumps in sales, investors should take a closer look. On the one hand, there may be considerable opportunities for share price gains. On the other hand, it must also be checked whether the development is sustainable or whether it is a one-off or seasonal event. BioNTech has impressively shown that the Company and the share can profit from a sudden increase in sales. Who is next? Investors should take a closer look at the vaccine developer Novavax and the diamond producer Diamcor - it could be worthwhile.
Read
Commented by Stefan Feulner on August 27th, 2021 | 11:53 CEST
BioNTech, XPhyto, Moderna - Boosters for the portfolio
Globally, infection numbers are rising dramatically due to the highly contagious Delta variant. According to the RKI, 12,626 new infections were reported in Germany alone, 4,226 more than a week ago. With the incidence rising above the authoritative level of 35, greater emphasis is again being placed on the rule, vaccinated, recovered or tested. As a result, demand for PCR or rapid tests is skyrocketing. Diagnostic companies, like vaccine producers, are in for a warm cash shower.
Read